Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy.

Probiotic Propionibacterium freudenreichii requires SlpB protein to mitigate mucositis induced by chemotherapy. Oncotarget. 2019 Dec 31;10(68):7198-7219 Authors: do Carmo FLR, Rabah H, Cordeiro BF, da Silva SH, Pessoa RM, Fernandes SOA, Cardoso VN, Gagnaire V, Deplanche M, Savassi B, Figueiroa A, Oliveira ER, Fonseca CC, Queiroz MIA, Rodrigues NM, Sandes SHC, Nunes ÁC, Lemos L, Alves JL, Faria AMC, Ferreira Ê, Le Loir Y, Jan G, Azevedo V Abstract Propionibacterium freudenreichii CIRM-BIA 129 (P. freudenreichii wild type, WT) is a probiotic bacterium, which exerts immunomodulatory effects. This strain possesses extractable surface proteins, including SlpB, which are involved in anti-inflammatory effect and in adhesion to epithelial cells. We decided to investigate the impact of slpB gene mutation on immunomodulation in vitro and in vivo. In an in vitro assay, P. freudenreichii WT reduced expression of IL-8 (p<0.0001) and TNF-α (p<0.0001) cytokines in LPS-stimulated HT-29 cells. P. freudenreichii ΔslpB, lacking the SlpB protein, failed to do so. Subsequently, both strains were investigated in vivo in a 5-FU-induced mucositis mice model. Mucositis is a common side effect of cytotoxic chemotherapy with 5-FU, characterized by mucosal injury, inflammation, diarrhea, and weight loss. The WT strain prevented weight loss, reduced inflammation and consequently histopathological scores. Furthermore, it regulated key markers, includin...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research